SAREPTA THERAPEUTICS, INC. (SRPT) Free cash flow 2016–2025
SAREPTA THERAPEUTICS, INC. (SRPT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$307.5MFY2025 · since FY2016: -$251.2M → -$307.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$307.5M | +10.3% |
| FY2024 | -$342.7M | +40.6% |
| FY2023 | -$577.1M | -62.0% |
| FY2022 | -$356.2M | +26.1% |
| FY2021 | -$481.7M | -2006.5% |
| FY2020 | $25.3M | +104.9% |
| FY2019 | -$516.1M | -14.7% |
| FY2018 | -$449.8M | -84.4% |
| FY2017 | -$244.0M | +2.9% |
| FY2016 | -$251.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SRPT financial trends
SRPT RevenueSRPT Net incomeSRPT Net marginSRPT Gross profitSRPT Gross marginSRPT Operating incomeSRPT Operating marginSRPT Operating cash flowSRPT Capital expendituresSRPT Return on equitySRPT Stock buybacksSRPT Dividends paidSRPT Total assetsSRPT Total liabilitiesSRPT Shareholders’ equitySRPT overview →